趋化因子在膀胱癌诊断中作用的研究进展
|
摘要
膀胱癌是临床泌尿系统最常见的肿瘤类型,具有较高的致死率和致残率,严重威胁人们的身体健康和生命安全。但是由于膀胱癌在早期诊断、复发监测以及预后评估中缺乏理想的肿瘤标志物,增加了膀胱癌的治疗难度。因此膀胱癌肿瘤标志物的研究是目前医学界研究的热点问题之一。趋化因子是一类具有免疫作用的超蛋白家族,它与肿瘤的生长和转移具有密切关系,对趋化因子的研究对于膀胱癌的诊疗和预后具有积极的意义。基于此,本文重点对近些年关于趋化因子在膀胱癌诊断中的作用研究进展进行综述,以期能够为临床膀胱癌的诊疗提供资料借鉴。
Bladder cancer is the most common type of tumor in the urinary system, with high mortality and disability, and it seriously threatens people's health and life safety. However, the lack of ideal tumor markers in early diagnosis, recurrence monitoring and prognostic evaluation of bladder cancer increases the difficulty of treatment of bladder cancer. Therefore, the research of tumor markers in bladder cancer is one of the hot topics in medical research. Chemokine is a type of superprotein family with immunity, and is closely related to the growth and metastasis of bladder cancer. The study of chemokines is of positive significance for the diagnosis, treatment and prognosis of bladder cancer. Based on this review, the role of chemokines in the diagnosis of bladder cancer in recent years was reviewed in order to provide reference for clinical diagnosis and treatment of bladder cancer.
Bladder cancer is the most common type of tumor in the urinary system, with high mortality and disability, and it seriously threatens people's health and life safety. However, the lack of ideal tumor markers in early diagnosis, recurrence monitoring and prognostic evaluation of bladder cancer increases the difficulty of treatment of bladder cancer. Therefore, the research of tumor markers in bladder cancer is one of the hot topics in medical research. Chemokine is a type of superprotein family with immunity, and is closely related to the growth and metastasis of bladder cancer. The study of chemokines is of positive significance for the diagnosis, treatment and prognosis of bladder cancer. Based on this review, the role of chemokines in the diagnosis of bladder cancer in recent years was reviewed in order to provide reference for clinical diagnosis and treatment of bladder cancer.
引文
[1]李凯,张素平.老年AIS患者的血清A-FABP和趋化因子CXCL12与AIS的发生及程度的关系[J].心血管康复医学杂志,2017,26(5):463-466.
[2]曹倪豪,周飞,陆伟,等.转染CXCR7重组质粒对膀胱癌5637细胞株增殖和侵袭的影响[J].国际泌尿系统杂志,2017,37(3):132-133.
[3]梁彦,崔飞伦.尿生存素联合液基细胞学检测对膀胱癌的诊断价值[J].医学研究生学报,2016,29(11):1211-1213.
[4]彭晓晖,梁培育,欧善际,等.趋化因子配体10及趋化因子受体3在膀胱癌中的表达及意义[J].重庆医学,2015(25):3491-3492.
[5]赵仕佳,叶向东,肖成林,等.血清CXCL5水平与原发性肌层浸润性膀胱癌外科治疗后复发的相关性研究[J].医学临床研究,2017,34(11):2217-2219.
[6]张志刚,倪锋,党建功,等.CXC趋化因子受体4在肾透明细胞癌中的表达及临床意义[J].中华泌尿外科杂志,2017,38(2):88-91.
[7]马琪,虞碧霞,陈俊丰,等.膀胱癌组织RON蛋白与CXC趋化因子受体4蛋白的表达及临床意义[J].中华实验外科杂志,2017,34(12):42-43.
[8]倪锋,杜永辉,郑亮,等.血清CXCL5对膀胱癌患者外科治疗后复发的影响[J].实用癌症杂志,2017,32(9):1444-1446.
[9]陈杰,虞伟星,马文勇,等.CCL5在膀胱癌中的表达及临床意义[J].浙江医学,2017,39(20):1756-1758.
[10]叶明宝,田俊强,常宏,等.SDF-1/CXCR4在膀胱癌组织中的表达及其与负性共刺激分子PD-L1、细胞凋亡和侵袭性的相关性研究[J].海南医学院学报,2017,23(6):736-738.
[11]周玉梅,房辉,刘晓爽,等.血清趋化因子水平与新诊断2型糖尿病患者认知功能的相关性研究[J].医学研究生学报,2017,30(9):958-962.
[12] Miyake M,Goodison S,Urquidi V,et al.Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways[J]. Lab Invest,2013,93(7):768-778.
[13]崔崎,韩玲,成俊,等.前列腺液中免疫球蛋白、细胞因子及趋化因子水平与慢性前列腺炎的关系[J].现代免疫学,2017(5):412-416.
[14]余婧,孙丽.中老年体检人群CCL18和CEA表达水平检测在膀胱癌的应用价值[J].检验医学与临床,2017,14(7):1006-1008.
[15]宋广智,袁海霞.血清趋化因子配体5预测膀胱癌外科治疗后复发的价值[J].实用临床医药杂志,2017(17):22-25.
[16] Urquidi V,Chang M,Dai Y,et al.IL-8 as a urinary biomarker for the detection of bladder cancer[J].BMCUrol,2012,12(6):12.
[2]曹倪豪,周飞,陆伟,等.转染CXCR7重组质粒对膀胱癌5637细胞株增殖和侵袭的影响[J].国际泌尿系统杂志,2017,37(3):132-133.
[3]梁彦,崔飞伦.尿生存素联合液基细胞学检测对膀胱癌的诊断价值[J].医学研究生学报,2016,29(11):1211-1213.
[4]彭晓晖,梁培育,欧善际,等.趋化因子配体10及趋化因子受体3在膀胱癌中的表达及意义[J].重庆医学,2015(25):3491-3492.
[5]赵仕佳,叶向东,肖成林,等.血清CXCL5水平与原发性肌层浸润性膀胱癌外科治疗后复发的相关性研究[J].医学临床研究,2017,34(11):2217-2219.
[6]张志刚,倪锋,党建功,等.CXC趋化因子受体4在肾透明细胞癌中的表达及临床意义[J].中华泌尿外科杂志,2017,38(2):88-91.
[7]马琪,虞碧霞,陈俊丰,等.膀胱癌组织RON蛋白与CXC趋化因子受体4蛋白的表达及临床意义[J].中华实验外科杂志,2017,34(12):42-43.
[8]倪锋,杜永辉,郑亮,等.血清CXCL5对膀胱癌患者外科治疗后复发的影响[J].实用癌症杂志,2017,32(9):1444-1446.
[9]陈杰,虞伟星,马文勇,等.CCL5在膀胱癌中的表达及临床意义[J].浙江医学,2017,39(20):1756-1758.
[10]叶明宝,田俊强,常宏,等.SDF-1/CXCR4在膀胱癌组织中的表达及其与负性共刺激分子PD-L1、细胞凋亡和侵袭性的相关性研究[J].海南医学院学报,2017,23(6):736-738.
[11]周玉梅,房辉,刘晓爽,等.血清趋化因子水平与新诊断2型糖尿病患者认知功能的相关性研究[J].医学研究生学报,2017,30(9):958-962.
[12] Miyake M,Goodison S,Urquidi V,et al.Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways[J]. Lab Invest,2013,93(7):768-778.
[13]崔崎,韩玲,成俊,等.前列腺液中免疫球蛋白、细胞因子及趋化因子水平与慢性前列腺炎的关系[J].现代免疫学,2017(5):412-416.
[14]余婧,孙丽.中老年体检人群CCL18和CEA表达水平检测在膀胱癌的应用价值[J].检验医学与临床,2017,14(7):1006-1008.
[15]宋广智,袁海霞.血清趋化因子配体5预测膀胱癌外科治疗后复发的价值[J].实用临床医药杂志,2017(17):22-25.
[16] Urquidi V,Chang M,Dai Y,et al.IL-8 as a urinary biomarker for the detection of bladder cancer[J].BMCUrol,2012,12(6):12.